Established cytotoxic chemotherapy 5 mcg/kg daily SC inj or IV infusion over 30 min, 1st dose to be given at least 24 hr after cytotoxic chemotherapy.
Patient treated w/ myeloablative therapy followed by bone marrow transplantation Initially 10 mcg/kg daily as 30-min or 24-hr IV infusion or continuous 24-hr SC infusion. 1st dose to be given at least 24 hr after cytotoxic chemotherapy or bone marrow infusion. Titrate dose against neutrophil response once neutrophil nadir has been passed.
PBPC mobilisation in patient undergoing myelosuppressive or myeloablative therapy followed by autologous peripheral blood progenitor cell transplantation Monotherapy: 10 mcg/kg daily as 24-hr SC continuous infusion or SC inj for 5-7 consecutive days. Timing of leukapheresis: 1 or 2 leukaphereses on days 5 & 6, additional leukaphereses may be necessary. Maintain filgrastim dosing until last leukapheresis.
Post-myelosuppressive chemotherapy 5 mcg/kg daily SC inj from 1st day of chemotherapy completion until expected neutrophil nadir is passed & neutrophil count has been to normal range.
PBPC mobilisation in normal donor prior to allogeneic PBPC transplantation 10 mcg/kg daily SC inj for 4-5 consecutive days.
Severe chronic & congenital neutropenia Initially 12 mcg/kg daily as single or in divided doses.
Idiopathic or cyclic neutropenia Initially 5 mcg/kg daily SC inj as single or in divided doses. Initial dose may be doubled or halved depending upon patient's response after 1-2 wk.
Patient w/ HIV infection Reversal of neutropenia: Initially 1 mcg/kg daily SC inj w/ titration up to max 4 mcg/kg daily until normal neutrophil count is reached & can be maintained. Maintaining normal neutrophil counts: Initial dose adjustment to alternate day dosing w/ 300 mcg daily SC inj.
Ped use in severe chronic neutropenia & cancer setting Adult dose receiving myelosuppressive cytotoxic chemotherapy.